theMednetRegister

Dementia   

Questions discussed in this category

How do you determine whether to continue anti-dementia medications (such as cholinesterase inhibitors) for patients with dementia when enrolling in hospice?
3 Answers available
What are your thoughts about lion's mane supplementation to slow the decline or improve cognitive capacity for those at risk of dementia?
1 Answer available
When is it useful to test for multiple amyloid-related biomarkers for patients undergoing work-up for cognitive impairment?
E.g., amyloid PET, CSF amyloid, blood-based amyloid.
1 Answer available
How do you manage sleep disturbances in patients with Alzheimer’s disease without relying heavily on deliriogenic medications?
2 Answers available
What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?
Specifically, what guidelines do you use to help determine this (if any)? 
1 Answer available
How do stroke-risk considerations affect your use of atypical antipsychotics for patients with dementia?
Related Q&A on antipsychotics in Alzheimer's.In light of the publication from Choma et al., PMID 41063545.
2 Answers available
Are there scenarios in which you would advise using benzodiazepines for the treatment of hyperactive delirium?
1 Answer available
How do you choose among SSRIs and dosing strategies for the management of behavioral and psychological symptoms of dementia?
What factors might drive decisions for different SSRIs and/or doses?
1 Answer available
What is your approach to deprescribing cholinesterase inhibitors and/or memantine in advancing stages of dementia?
2 Answers available
What would be your approach to the consideration of the use of antiamyloid monoclonal antibodies for nonamnestic Alzheimer's disease with a positive biomarker for brain amyloid pathology?
E.g., primary progressive aphasia
2 Answers available
How do you approach evaluating sudden mental status changes in telepsychiatry patients, particularly older adults, when medical causes such as infection or metabolic disturbance may be contributing factors?
What red flags prompt you to recommend urgent in-person evaluation? Are there particular strategies or screening questions you have found helpful to d...
1 Answer available
Would you recommend a GLP-1 agonist as an option to reduce the risk of dementia in patients with a strong family history?
As studied in Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related De...
1 Answer available
What is your antipsychotic of choice and general titration regimen in the outpatient setting for a patient with dementia and behavioral disturbances (assuming reversible causes such as urinary retention, constipation, etc. have been addressed)?
2 Answers available
How do you approach balancing the treatment of urinary incontinence with anticholinergic medications with the use of cholinesterase inhibitors in dementia?
1 Answer available
How do you approach individualizing A1c goals in patients with dementia?
2 Answers available
What is your approach to determining eligibility for hospice in persons with Alzheimer's disease?
1 Answer available
How do you select between antipsychotics in the treatment of delirium refractory to nonpharmacological management in hospitalized older adults with dementia?
From a geriatrics harm-reduction standpoint, can we recommend any particulars regarding dosing or selection of therapies when used as a last resort?
1 Answer available
How do you treat agitation in progressive supranuclear palsy?
Would you consider benzodiazepines for agitation in progressive supranuclear palsy? What other treatment strategies would you consider? 
1 Answer available
What are your preferred strategies for managing sundowning in patients with moderate Alzheimer’s disease?
2 Answers available
Do you recommend life long aspirin 81 mg daily for non-specific T2 white matter hyper-intensities on MRI brain?
7 Answers available


Papers discussed in this category

Front Neurol, 2021 Jul 01
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.
Semin Neurol, 2022 Apr
Medication Management of Neuropsychiatric Symptoms in Neurological Conditions: A Dimensional Transdiagnostic Approach.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2018-02
A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.
JAMA internal medicine, 2025 May 01
Continued Use of Cholinesterase Inhibitors and Memantine in Hospice.
Alzheimer's & dementia (New York, N. Y.), 2022 Jan 31
CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia.
The Medical journal of Australia, 2019 Feb 16
Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.
The American journal of psychiatry, 2016-05-01
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
The American journal of psychiatry, 2016-05-01
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study.
JAMA, 2014 Feb 19
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Frontiers in aging neuroscience, 2023 Mar 03
Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis.
Journal of Alzheimer's disease : JAD, 2020
The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP).
Journal of the American Geriatrics Society, 2025 Apr 28
Treatment of Inappropriate Sexual Behavior in Persons With Dementia: A Systematic Review.
Journal of the American Geriatrics Society, 2016 Mar 23
Antipsychotic Medication for Prevention and Treatment of Delirium in Hospitalized Adults: A Systematic Review and Meta-Analysis.
The Cochrane database of systematic reviews, 2018 Jun 18
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.
JAMA, 2011-09-28
Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
The Cochrane database of systematic reviews, 2014-03-21
Pharmacotherapies for sleep disturbances in Alzheimer's disease.
Translational psychiatry, 2022 Apr 01
Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings.
Journal of sleep research, 2020 Dec 02
Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2016 Jan 27
Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2022 Dec 01
Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.
CNS drugs, 2024 Aug 09
Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.